BAFF / BLyS (Protein | Antibody | cDNA Clone | ELISA Kit)

All BAFF / BLyS reagents are produced in house and quality controlled, including 6 BAFF / BLyS Antibody, 40 BAFF / BLyS Gene, 2 BAFF / BLyS IP Kit, 4 BAFF / BLyS Lysate, 6 BAFF / BLyS Protein, 2 BAFF / BLyS qPCR. All BAFF / BLyS reagents are ready to use.

More Product Popular With Customers

BAFF / BLyS Background

B lymphocyte stimulator (BLyS), also known as TNFSF13B, CD257 and BAFF, is single-pass type II membrane protein, which belongs to the tumor necrosis factor family. BAFF is abundantly expressed in peripheral blood Leukocytes and is specifically expressed in monocytes and macrophages. BAFF is a cytokine and serves as a ligand for receptors TNFRSF13B (TACI), TNFRSF17 (BCMA), and TNFRSF13C (BAFFR). These receptors is a prominent factor in B cell differentiation, homeostasis, and selection. BLyS levels affect survival signals and selective apoptosis of autoantibody-producing B cells. Thus, it acts as a potent B cell activator and has been shown to play an important role in the proliferation and differentiation of B cells. Overexpression of BLyS in mice can lead to clinical and serological features of systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS). BLyS as an attractive therapeutic target in human rheumatic diseases. The ability of BLyS to regulate both the size and repertoire of the peripheral B cell compartment raises the possibility that BLyS and antagonists thereof may form the basis of a therapeutic trichotomy. As an agonist, BLyS protein may enhance humoral immunity in congenital or acquired immunodeficiencies such as those resulting from viral infection or cancer therapy.

BAFF / BLyS References

  • Nardelli B, et al. (2002) B lymphocyte stimulator (BLyS): a therapeutic trichotomy for the treatment of B lymphocyte diseases. Leuk Lymphoma. 43(7): 1367-73.
  • Stohl W. (2006) Therapeutic targeting of B lymphocyte stimulator (BLyS) in the rheumatic diseases. Endocr Metab Immune Disord Drug Targets. 6(4): 51-8.
  • Cancro MP, et al. (2009) The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest. 119(5): 1066-73.
彩票大奖得主捐赠 新手炒股怎样买股票 今日股票指数 江苏11选五最大遗漏号码 上班炒股 黑龙江p62开奖结果今天晚上 东方6+1计划 期货配资交易 pc蛋蛋赔率投注软件 五分快三通用版破解器下载 娱乐圈电玩城